Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Quince Therapeutics, Inc. (NASDAQ: QNCX) announced that its Board of Directors has unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital, which offered $1.60 per share in cash. The Board determined that the offer undervalues the company and is not aligned with the best interests of Quince and its shareholders. This decision underscores Quince's strategy to continue developing innovative therapeutics aimed at transforming patient lives. The company is actively pursuing opportunities to enhance its clinical pipeline with promising assets.